EFFECT OF ZOLEDRONIC AND IBANDRONIC ACIDS ON BONE METABOLISM IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

Abstract


In open prospective study we determine the efficacy of zoledronic and ibandronic acids on bone metabolism markers and bone mineral density in women with postmenopausal osteoporosis. 225 women with postmenopausal osteoporosis treated with zoledronic acid in dose 5 mg, intravenously, once a year and 64 women treated ibandronic acid were followed up. The investigators assessed clinical and medical history data, evaluated the gynecological and somatic statuses, and made laboratory and instrumental studies: clinical, biochemical blood tests, general urinalysis, determination of serum bone metabolism markers (B-Crosslaps, osteocalcin), osteodensitometry and electrocardiography, therapist ’s examination if needed. Therapy with zoledronic acid 5 mg once a year and ibandronic acid 150 mg once a month was followed by a significant reduction in resorption markers (B-Crosslaps) just following one month. Formation markers decreased to a lesser degree, which was indicative of preserved positive bone remodeling balance during the therapy. Determination of biochemical markers of bone remodeling permits assessment of an individual patient response to antiresorbtive therapy just in the first month after infusion. Zoledronic acid or ibandronic acid therapy exerts a rapid and potent effect on bone metabolism, mainly by inhibiting the resorption processes.

About the authors

O V Yakushevskaya

Email: ykushox83@mail.ru
m.n.s. otdeleniya ginekologicheskoy endokrinologii

E V Bordakova

aspirant 3-go goda obucheniya otdeleniya ginekologicheskoy endokrinologii

A A Gavisova

nauch.sotr., k.m.n., vrach otdeleniya ginekologicheskoy endokrinologii

S Yu Kuznetsov

k.m.n., vrach otdeleniya ginekologicheskoy endokrinologii

S V Yureneva

ved.nauch.sotr, d.m.n., vrach otdeleniya ginekologicheskoy endokrinologii

T Yu Ivanets

zav.nauchno-diagnosticheskoy laboratoriey

V P Smetnik

d.m.n., professor, vrach vysshey kategorii, zasluzhennyy deyatel' nauki RF

G T Sukhikh

akademik RAMN, direktor

References

  1. Беневоленская Л.И., Лесняк О.М. Клинические рекомендации. Диагностика, профилактика и лечение остеопо-роза (2-е издание) / «ГЕОТАР-Медиа» — 2009.
  2. Лесняк О.М. «Аудит состояния проблемы остеопороза в странах востночной европы и центральной азии 2010» // Остеопороз и остеопения. — 2. 2011. — С.3—6.
  3. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико-социальные последствия (по данным многоцентрового исследования) // Остеопороз и остеопении. — 2002. — № 1. — С. 8—11.
  4. Михайлов Е.Е., Беневоленская Л.И. Эпидемиология остеопороза и переломов. // В кн.«Руководство по остеопорозу». — М.: Бином, 2003. — С.10—53.
  5. American association of endocrinologists (AACE) medical guidelines for the prevenyion and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 // Endocr. Prac. — 2003. — Vol. 9, № 6. — P. 544—564.
  6. Baro F.B., Rodrigez B., Guinot M. Osteopenia and fractures. // Meeting Abstracts of the 12th World Congress on the Menopause. Climacteric 2008; 11(Suppl.2), P. 255.
  7. Black D.M., Delmas P.D., Eastell R. et al. Once-yearly Zoledronic acid for treatment of postmenopausal osteoporosis // New Engl.J.Med. — 2007, May 3. — № 356(18), Р. 1809—1822.
  8. Brown J.P., Josse R.G. Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada // CMAJ. -2002. — 167 (10 suppl). — P. S1—S34.
  9. Delmas P.D., Eastell R., Garnero P. et al. [Scientific Advisors of the International Osteoporosis Foundation]. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation // Osteoporosis Int. — 2000. — 11(Suppl 6). — S2—17.
  10. Institute for Clinical Systems Improvement (ICST) Health Care Guideline: Diagnosis and Treatment of osteoporosis. — 3rd edition. — July 2004. — www.ICST.org.
  11. Fox K.M., Cummings S.R., Kelsey J.I. Family history and risk of osteoporotic fracture. // Osteoporosis Int. 1998. Vol. 8. P. 557—562.
  12. Garnero P. Markers of bone turnover for the prediction of fracture risk // Osteoporosis Int. — 2000. — № 11 (Suppl 6). — P. S55—65.
  13. Green A.D., Colon-Emeric C.S. et al. Does this woman have osteoporosis? // JAMA. — 2004. — № 292 (23). — P. 2890—2900.
  14. Hadji P. Managing bone health with Zoledronic acid: a review of randomized clinical stady resalt // Climacteric — 2011. — № 14 — Р. 321—332.
  15. Keith Thompson, Michael J. Rogers. Statins Prevent Bisphosphonate-induced γ,δ-T-cell Proliferation and Activation in vitro. // J. Bone and Miner. Res. — 2004. — Vol. 19. — P.278—288.
  16. Reid D., Delmas P., Eastell et al. The Addition of Once-Yearly Zoledronic Acid 5 mg to Non-Bisphosphonate Treatment for Osteoporosis Reduce Fractures in Postmenopausal Women: The HORIZON PFT. // 19th Annual Meeting. - Orlando, USA. — 2008. — P. 36.7.
  17. Reginster J.Y., Wilson K.M., Dumont E. et al. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study // J Clin Endocrinol Metab. 2005, Sep; 90(9): 5018—5024.

Statistics

Views

Abstract - 738

PDF (Russian) - 452

Cited-By


PlumX

Dimensions


Copyright (c) 2012 Yakushevskaya O.V., Bordakova E.V., Gavisova A.A., Kuznetsov S.Y., Yureneva S.V., Ivanets T.Y., Smetnik V.P., Sukhikh G.T.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies